Pathologic fractures correlate with reduced survival in patients with malignant bone disease
BACKGROUND. Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease. METHODS. A Cox regression model was used to estimate the effect of fractures (time‐dependent variable...
Saved in:
Published in | Cancer Vol. 110; no. 8; pp. 1860 - 1867 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
15.10.2007
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND.
Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease.
METHODS.
A Cox regression model was used to estimate the effect of fractures (time‐dependent variable) on survival in patients with stage III multiple myeloma or bone metastases from solid tumors enrolled in 3 large trials. Patients were randomized to receive zoledronic acid, pamidronate, or placebo every 3–4 weeks for up to 24 months (prostate cancer, breast cancer, and multiple myeloma) or up to 21 months (lung and other solid tumors).
RESULTS.
A total of 3049 patients with multiple myeloma (n = 513), breast (n = 1130), prostate (n = 640), or lung cancer or other solid tumors (n = 766) were included in this analysis. Patients with multiple myeloma had the highest fracture incidence (43%), followed by breast (35%), prostate (19%), and lung cancer (17%). In all tumor types except lung, pathologic fracture was associated with a significant increase in risk of death, and breast cancer patients had the greatest increased risk. After adjustment for baseline characteristics, including performance status and prior skeletal complications, breast cancer patients who developed a pathologic fracture on study had a significant 32% increased risk of death relative to patients without a fracture (hazard ratio = 1.32; P < .01); patients with multiple myeloma or prostate cancer had a >20% increased risk of death.
CONCLUSIONS.
These results suggest that fractures are associated with increased risk of death in patients with malignant bone disease. Therefore, preventing fractures is an important goal of therapy. Cancer 2007. © 2007 American Cancer Society.
Data from 3 randomized, double‐blind, controlled phase 3 trials of zoledronic acid were retrospectively analyzed to assess the association between the occurrence of pathologic fractures and survival in patients with bone metastases secondary to breast cancer, multiple myeloma, prostate cancer, or nonsmall‐cell lung cancer or other solid tumors. The results suggest that an increased risk of death is associated with the occurrence of fractures in patients with malignant bone disease. |
---|---|
AbstractList | BACKGROUNDData from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease.METHODSA Cox regression model was used to estimate the effect of fractures (time-dependent variable) on survival in patients with stage III multiple myeloma or bone metastases from solid tumors enrolled in 3 large trials. Patients were randomized to receive zoledronic acid, pamidronate, or placebo every 3-4 weeks for up to 24 months (prostate cancer, breast cancer, and multiple myeloma) or up to 21 months (lung and other solid tumors).RESULTSA total of 3049 patients with multiple myeloma (n = 513), breast (n = 1130), prostate (n = 640), or lung cancer or other solid tumors (n = 766) were included in this analysis. Patients with multiple myeloma had the highest fracture incidence (43%), followed by breast (35%), prostate (19%), and lung cancer (17%). In all tumor types except lung, pathologic fracture was associated with a significant increase in risk of death, and breast cancer patients had the greatest increased risk. After adjustment for baseline characteristics, including performance status and prior skeletal complications, breast cancer patients who developed a pathologic fracture on study had a significant 32% increased risk of death relative to patients without a fracture (hazard ratio = 1.32; P < .01); patients with multiple myeloma or prostate cancer had a >20% increased risk of death.CONCLUSIONSThese results suggest that fractures are associated with increased risk of death in patients with malignant bone disease. Therefore, preventing fractures is an important goal of therapy. BACKGROUND. Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease. METHODS. A Cox regression model was used to estimate the effect of fractures (time‐dependent variable) on survival in patients with stage III multiple myeloma or bone metastases from solid tumors enrolled in 3 large trials. Patients were randomized to receive zoledronic acid, pamidronate, or placebo every 3–4 weeks for up to 24 months (prostate cancer, breast cancer, and multiple myeloma) or up to 21 months (lung and other solid tumors). RESULTS. A total of 3049 patients with multiple myeloma (n = 513), breast (n = 1130), prostate (n = 640), or lung cancer or other solid tumors (n = 766) were included in this analysis. Patients with multiple myeloma had the highest fracture incidence (43%), followed by breast (35%), prostate (19%), and lung cancer (17%). In all tumor types except lung, pathologic fracture was associated with a significant increase in risk of death, and breast cancer patients had the greatest increased risk. After adjustment for baseline characteristics, including performance status and prior skeletal complications, breast cancer patients who developed a pathologic fracture on study had a significant 32% increased risk of death relative to patients without a fracture (hazard ratio = 1.32; P < .01); patients with multiple myeloma or prostate cancer had a >20% increased risk of death. CONCLUSIONS. These results suggest that fractures are associated with increased risk of death in patients with malignant bone disease. Therefore, preventing fractures is an important goal of therapy. Cancer 2007. © 2007 American Cancer Society. Data from 3 randomized, double‐blind, controlled phase 3 trials of zoledronic acid were retrospectively analyzed to assess the association between the occurrence of pathologic fractures and survival in patients with bone metastases secondary to breast cancer, multiple myeloma, prostate cancer, or nonsmall‐cell lung cancer or other solid tumors. The results suggest that an increased risk of death is associated with the occurrence of fractures in patients with malignant bone disease. Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease. A Cox regression model was used to estimate the effect of fractures (time-dependent variable) on survival in patients with stage III multiple myeloma or bone metastases from solid tumors enrolled in 3 large trials. Patients were randomized to receive zoledronic acid, pamidronate, or placebo every 3-4 weeks for up to 24 months (prostate cancer, breast cancer, and multiple myeloma) or up to 21 months (lung and other solid tumors). A total of 3049 patients with multiple myeloma (n = 513), breast (n = 1130), prostate (n = 640), or lung cancer or other solid tumors (n = 766) were included in this analysis. Patients with multiple myeloma had the highest fracture incidence (43%), followed by breast (35%), prostate (19%), and lung cancer (17%). In all tumor types except lung, pathologic fracture was associated with a significant increase in risk of death, and breast cancer patients had the greatest increased risk. After adjustment for baseline characteristics, including performance status and prior skeletal complications, breast cancer patients who developed a pathologic fracture on study had a significant 32% increased risk of death relative to patients without a fracture (hazard ratio = 1.32; P < .01); patients with multiple myeloma or prostate cancer had a >20% increased risk of death. These results suggest that fractures are associated with increased risk of death in patients with malignant bone disease. Therefore, preventing fractures is an important goal of therapy. Abstract BACKGROUND. Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease. METHODS. A Cox regression model was used to estimate the effect of fractures (time‐dependent variable) on survival in patients with stage III multiple myeloma or bone metastases from solid tumors enrolled in 3 large trials. Patients were randomized to receive zoledronic acid, pamidronate, or placebo every 3–4 weeks for up to 24 months (prostate cancer, breast cancer, and multiple myeloma) or up to 21 months (lung and other solid tumors). RESULTS. A total of 3049 patients with multiple myeloma (n = 513), breast (n = 1130), prostate (n = 640), or lung cancer or other solid tumors (n = 766) were included in this analysis. Patients with multiple myeloma had the highest fracture incidence (43%), followed by breast (35%), prostate (19%), and lung cancer (17%). In all tumor types except lung, pathologic fracture was associated with a significant increase in risk of death, and breast cancer patients had the greatest increased risk. After adjustment for baseline characteristics, including performance status and prior skeletal complications, breast cancer patients who developed a pathologic fracture on study had a significant 32% increased risk of death relative to patients without a fracture (hazard ratio = 1.32; P < .01); patients with multiple myeloma or prostate cancer had a >20% increased risk of death. CONCLUSIONS. These results suggest that fractures are associated with increased risk of death in patients with malignant bone disease. Therefore, preventing fractures is an important goal of therapy. Cancer 2007. © 2007 American Cancer Society. Data from 3 randomized, double‐blind, controlled phase 3 trials of zoledronic acid were retrospectively analyzed to assess the association between the occurrence of pathologic fractures and survival in patients with bone metastases secondary to breast cancer, multiple myeloma, prostate cancer, or nonsmall‐cell lung cancer or other solid tumors. The results suggest that an increased risk of death is associated with the occurrence of fractures in patients with malignant bone disease. |
Author | Saad, Fred Coleman, Robert Smith, Matthew Lipton, Allan Cook, Richard Chen, Yin‐Miao |
Author_xml | – sequence: 1 givenname: Fred surname: Saad fullname: Saad, Fred email: fred.saad@umontreal.ca – sequence: 2 givenname: Allan surname: Lipton fullname: Lipton, Allan – sequence: 3 givenname: Richard surname: Cook fullname: Cook, Richard – sequence: 4 givenname: Yin‐Miao surname: Chen fullname: Chen, Yin‐Miao – sequence: 5 givenname: Matthew surname: Smith fullname: Smith, Matthew – sequence: 6 givenname: Robert surname: Coleman fullname: Coleman, Robert |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19139264$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17763372$$D View this record in MEDLINE/PubMed |
BookMark | eNp90M9LHDEUB_BQlLpue-kfUHLRgzA2vyaZOcqitiAqpYKHwhBf3mhKNrNNZpT9742dBW89hRc-fN_je0j24hCRkC-cnXLGxDeIkE6FaFv-gSw4a03FuBJ7ZMEYa6payfsDcpjznzIaUcuP5IAbo6U0YkF-39rxaQjDowfaJwvjlDBTGFLCYEekL358ogndBOhontKzf7aB-kg3dvQYxzyLtQ3-Mdo40odyG3U-o834iez3NmT8vHuX5O7i_Nfqe3V1c_ljdXZVgWwlr6zobdNqaLRxFk0PvC5fhjMFdc2cU6hdo0SvWKNBC4ktVyAUmIZpJ6SQS3I8527S8HfCPHZrnwFDsBGHKXe6kbXWjSnwZIaQhpwT9t0m-bVN246z7q3L7q3L7l-XBX_dpU4Pa3TvdFdeAUc7YDPYUOqL4PO7Kxmt0Ko4PrsXH3D7n5Xd6nr1c17-CjNPjpo |
CODEN | CANCAR |
CitedBy_id | crossref_primary_10_1186_s12885_023_11495_w crossref_primary_10_1016_j_ctrv_2011_09_003 crossref_primary_10_3390_jcm11113088 crossref_primary_10_1148_radiol_13121351 crossref_primary_10_4252_wjsc_v6_i3_322 crossref_primary_10_3390_cancers11091332 crossref_primary_10_15406_jcpcr_2017_08_00269 crossref_primary_10_1053_j_seminoncol_2010_06_007 crossref_primary_10_2147_IJN_S268398 crossref_primary_10_1016_j_clon_2013_01_008 crossref_primary_10_5435_JAAOSGlobal_D_20_00141 crossref_primary_10_1053_j_seminoncol_2010_06_009 crossref_primary_10_4155_cli_10_25 crossref_primary_10_1016_j_jvir_2013_08_023 crossref_primary_10_3390_ijms241512508 crossref_primary_10_1016_j_clml_2017_09_005 crossref_primary_10_1007_s11914_012_0131_2 crossref_primary_10_3390_jcm10173973 crossref_primary_10_1016_S2152_2650_20_30457_2 crossref_primary_10_1586_erd_12_27 crossref_primary_10_1016_j_radonc_2022_06_002 crossref_primary_10_33590_emjurol_10312887 crossref_primary_10_1148_rycan_2021200137 crossref_primary_10_1002_oa_1084 crossref_primary_10_1016_j_jbo_2022_100443 crossref_primary_10_1016_j_jbo_2017_10_003 crossref_primary_10_1182_blood_2010_09_308171 crossref_primary_10_1016_j_breast_2009_07_001 crossref_primary_10_1016_j_jradnu_2017_12_006 crossref_primary_10_4137_CMT_S1958 crossref_primary_10_1096_fj_13_231233 crossref_primary_10_1007_s00256_022_04032_6 crossref_primary_10_1016_j_ejphar_2013_03_034 crossref_primary_10_1111_ecc_12761 crossref_primary_10_1016_j_bone_2017_11_018 crossref_primary_10_1111_bjh_13584 crossref_primary_10_1016_j_jbo_2022_100416 crossref_primary_10_1016_j_ctrv_2012_12_004 crossref_primary_10_1007_s11060_015_1813_2 crossref_primary_10_1158_1078_0432_CCR_08_1572 crossref_primary_10_1055_s_0041_1740351 crossref_primary_10_2217_ahe_09_8 crossref_primary_10_3892_ol_2017_7670 crossref_primary_10_3109_0284186X_2011_633555 crossref_primary_10_1016_S1470_2045_13_70174_8 crossref_primary_10_1007_s00520_013_2022_1 crossref_primary_10_1634_theoncologist_2009_0078 crossref_primary_10_1101_cshperspect_a031286 crossref_primary_10_3390_ijms20194805 crossref_primary_10_2967_jnumed_123_266654 crossref_primary_10_1002_cncr_23529 crossref_primary_10_1111_bcpt_12854 crossref_primary_10_5435_JAAOS_D_23_00297 crossref_primary_10_1182_blood_2011_10_384784 crossref_primary_10_1111_bjh_13577 crossref_primary_10_1016_j_cllc_2015_06_004 crossref_primary_10_1016_j_jconrel_2019_08_038 crossref_primary_10_1016_j_pmrj_2018_02_006 crossref_primary_10_1053_j_seminoncol_2010_06_001 crossref_primary_10_1016_j_clgc_2013_04_008 crossref_primary_10_1053_j_seminoncol_2010_06_002 crossref_primary_10_3390_cancers13020201 crossref_primary_10_1186_s13244_019_0820_9 crossref_primary_10_1016_j_wneu_2015_06_008 crossref_primary_10_4103_jcvjs_JCVJS_56_20 crossref_primary_10_1016_j_bone_2021_115998 crossref_primary_10_1186_1756_9966_27_11 crossref_primary_10_1016_j_ocl_2022_08_010 crossref_primary_10_1007_s10147_012_0414_8 crossref_primary_10_1007_s10549_011_1721_x crossref_primary_10_1158_1078_0432_CCR_15_1864 crossref_primary_10_1016_j_ctrv_2009_11_005 crossref_primary_10_1177_1758834014521110 crossref_primary_10_1002_cam4_4125 crossref_primary_10_1038_s41408_018_0098_z crossref_primary_10_1016_j_canlet_2017_05_029 crossref_primary_10_1371_journal_pone_0019956 crossref_primary_10_1007_s00330_022_08955_5 crossref_primary_10_1007_s10585_014_9686_x crossref_primary_10_1016_j_injury_2018_09_044 crossref_primary_10_1148_radiol_2015150799 crossref_primary_10_3892_or_2016_4796 crossref_primary_10_1007_s11899_012_0135_0 crossref_primary_10_1586_eem_11_4 crossref_primary_10_1177_2309499017716243 crossref_primary_10_1016_j_otsr_2020_05_007 crossref_primary_10_1002_cncr_25529 crossref_primary_10_1097_SPC_0b013e328349652d crossref_primary_10_1177_1758834015582178 crossref_primary_10_1111_ejh_12205 crossref_primary_10_1359_jbmr_090901 crossref_primary_10_1136_bcr_2019_231219 crossref_primary_10_1177_21514593231153106 crossref_primary_10_3390_ijms241512436 crossref_primary_10_1007_s00384_020_03612_z crossref_primary_10_1586_era_10_136 crossref_primary_10_1155_2020_8408943 crossref_primary_10_1158_2767_9764_CRC_22_0180 crossref_primary_10_1002_jbmr_2193 crossref_primary_10_3816_CLC_2009_n_030 crossref_primary_10_3111_13696998_2011_650489 crossref_primary_10_1007_s00520_013_1991_4 crossref_primary_10_1016_j_recot_2015_05_003 crossref_primary_10_1016_j_clinthera_2009_05_009 crossref_primary_10_18332_tid_136419 crossref_primary_10_2478_rojost_2022_0006 crossref_primary_10_1295_koron_2017_0077 crossref_primary_10_1007_s00270_022_03340_7 crossref_primary_10_1097_01_COT_0000388033_23565_f8 crossref_primary_10_1097_CCO_0000000000000071 crossref_primary_10_5435_JAAOSGlobal_D_20_00090 crossref_primary_10_1080_08998280_2023_2298667 crossref_primary_10_1016_j_wneu_2024_04_091 crossref_primary_10_1007_s00270_023_03417_x crossref_primary_10_3389_fonc_2021_692788 crossref_primary_10_1016_j_lungcan_2009_08_020 crossref_primary_10_1016_j_xnsj_2024_100317 crossref_primary_10_1016_j_drudis_2014_04_004 crossref_primary_10_1177_1756287212453079 crossref_primary_10_1302_0301_620X_100B12_BJJ_2018_0697_R1 crossref_primary_10_1586_14737167_2013_820959 crossref_primary_10_1016_j_clml_2021_09_015 crossref_primary_10_1080_02656736_2018_1508760 crossref_primary_10_1517_14728222_2011_586634 crossref_primary_10_1593_neo_10610 crossref_primary_10_1186_s40902_016_0052_6 crossref_primary_10_1016_j_jbo_2013_04_001 crossref_primary_10_1097_CORR_0000000000001303 crossref_primary_10_1586_erm_11_44 crossref_primary_10_1016_j_suronc_2013_02_008 crossref_primary_10_1016_j_clon_2011_03_010 crossref_primary_10_2214_AJR_08_2002 crossref_primary_10_1634_theoncologist_2007_0245 crossref_primary_10_1002_jbmr_2789 crossref_primary_10_1016_j_jbo_2017_08_003 crossref_primary_10_1016_j_urolonc_2010_08_007 crossref_primary_10_1016_j_wneu_2024_03_084 crossref_primary_10_1080_17474086_2019_1640115 crossref_primary_10_1016_j_amjms_2018_12_006 crossref_primary_10_1016_j_jbo_2020_100289 crossref_primary_10_1016_j_ctrv_2016_02_002 crossref_primary_10_1016_j_critrevonc_2011_03_007 crossref_primary_10_1016_j_jor_2023_03_008 crossref_primary_10_3390_medicina60060881 crossref_primary_10_1097_BOT_0000000000002360 crossref_primary_10_3892_mco_2014_410 crossref_primary_10_1186_s41747_018_0082_1 crossref_primary_10_3389_fendo_2018_00344 crossref_primary_10_1016_j_juro_2010_03_034 crossref_primary_10_2106_JBJS_H_00175 crossref_primary_10_1016_j_jbo_2013_01_002 crossref_primary_10_1016_S1040_8428_11_70006_3 crossref_primary_10_1136_spcare_2023_004582 crossref_primary_10_1016_j_ddstr_2011_05_001 crossref_primary_10_1002_jbm4_10252 crossref_primary_10_1016_j_critrevonc_2008_07_008 crossref_primary_10_1177_1758835919855235 crossref_primary_10_2217_pmt_2023_0069 crossref_primary_10_3390_cancers15143601 crossref_primary_10_5435_JAAOS_D_23_00332 crossref_primary_10_3389_fgene_2021_640954 crossref_primary_10_1177_107327481201900209 crossref_primary_10_1302_2058_5241_5_190013 crossref_primary_10_1007_s00117_013_2626_y crossref_primary_10_4155_cli_12_38 crossref_primary_10_1200_JOP_18_00431 crossref_primary_10_1002_jbm4_10125 crossref_primary_10_1177_2192568218768774 crossref_primary_10_1093_jbmrpl_ziae066 crossref_primary_10_1007_s00402_020_03581_6 crossref_primary_10_1186_s12935_021_02258_3 crossref_primary_10_1038_leu_2014_69 crossref_primary_10_1007_s11914_017_0344_5 crossref_primary_10_1002_jbmr_4539 crossref_primary_10_1186_1471_2407_9_272 crossref_primary_10_3390_ijms17091391 crossref_primary_10_1097_MLR_0000000000000539 crossref_primary_10_1586_ehm_09_36 crossref_primary_10_1155_2022_5211329 crossref_primary_10_1002_ajh_23164 crossref_primary_10_1186_s40880_016_0102_6 crossref_primary_10_1007_s12185_011_0971_z crossref_primary_10_3109_10428194_2014_924117 crossref_primary_10_1016_j_jbo_2023_100507 crossref_primary_10_3389_fimmu_2022_980456 crossref_primary_10_1634_theoncologist_2015_0085 crossref_primary_10_1016_j_crad_2021_05_013 crossref_primary_10_1016_j_ijrobp_2023_07_001 crossref_primary_10_1093_neuros_nyy017 crossref_primary_10_1016_j_injury_2014_10_038 crossref_primary_10_26693_jmbs06_05_116 crossref_primary_10_3390_cancers13174320 crossref_primary_10_1586_era_10_191 crossref_primary_10_1016_S1877_1203_17_30058_7 crossref_primary_10_1088_1748_605X_ad5ba5 crossref_primary_10_1111_ejh_13044 crossref_primary_10_1592_phco_28_12_1511 crossref_primary_10_3390_cancers15092657 crossref_primary_10_1080_10428194_2017_1323272 crossref_primary_10_1245_s10434_020_08819_6 crossref_primary_10_1186_s12885_015_1797_5 crossref_primary_10_1016_j_jbo_2017_09_003 crossref_primary_10_1007_s10140_020_01753_w crossref_primary_10_1016_j_bone_2016_02_019 crossref_primary_10_1155_2020_3985315 crossref_primary_10_1158_1078_0432_CCR_13_2275 crossref_primary_10_1002_j_1875_9114_2011_01092_x crossref_primary_10_1016_j_recote_2015_09_006 crossref_primary_10_1038_pcan_2016_62 crossref_primary_10_7759_cureus_46162 crossref_primary_10_1016_j_jbo_2016_07_003 crossref_primary_10_1097_COC_0b013e3181deb9e5 crossref_primary_10_1016_j_jbo_2016_07_001 crossref_primary_10_1016_j_injury_2016_07_047 crossref_primary_10_1590_1413_785220182606201669 crossref_primary_10_1155_2014_167035 crossref_primary_10_1002_jcp_25351 crossref_primary_10_1177_1756287212441234 crossref_primary_10_1016_j_clml_2019_02_010 crossref_primary_10_1111_j_1464_410X_2008_08249_x crossref_primary_10_1016_j_clgc_2018_11_008 crossref_primary_10_35772_ghm_2021_01110 crossref_primary_10_1007_s10198_015_0716_7 crossref_primary_10_1177_10499091241240134 crossref_primary_10_1111_bjh_13928 crossref_primary_10_1097_01_blo_0000534678_44152_ee crossref_primary_10_2106_JBJS_OA_22_00070 crossref_primary_10_3390_ijms22083840 crossref_primary_10_1016_j_bone_2016_05_014 crossref_primary_10_1007_s12018_017_9227_7 crossref_primary_10_1016_j_critrevonc_2010_07_017 crossref_primary_10_1186_s13046_018_0813_4 crossref_primary_10_1586_14737167_2015_1024662 crossref_primary_10_1158_1541_7786_MCR_16_0242_T crossref_primary_10_1016_j_urolonc_2018_03_023 crossref_primary_10_1200_JCO_2016_68_3482 crossref_primary_10_1038_nrc3500 crossref_primary_10_1159_000495473 crossref_primary_10_1634_theoncologist_2014_0328 crossref_primary_10_3760_cma_j_issn_0366_6999_20132435 crossref_primary_10_1097_BRS_0000000000004093 crossref_primary_10_1016_j_bcp_2016_06_020 crossref_primary_10_1016_j_crad_2022_05_022 crossref_primary_10_1186_s12885_020_6596_y crossref_primary_10_3390_cancers13153662 crossref_primary_10_1308_rcsann_2017_0049 crossref_primary_10_1038_s41419_018_0807_3 crossref_primary_10_1158_1078_0432_CCR_15_2134 crossref_primary_10_17085_apm_2018_13_2_222 crossref_primary_10_5847_wjem_j_issn_1920_8642_2014_04_011 crossref_primary_10_3390_cancers13102287 crossref_primary_10_1097_CAD_0000000000001051 crossref_primary_10_1016_j_jbo_2012_12_004 crossref_primary_10_1016_j_jsbmb_2020_105588 crossref_primary_10_1093_neuonc_noac094 crossref_primary_10_1016_j_jval_2010_11_014 crossref_primary_10_2147_CMAR_S330591 crossref_primary_10_3389_fmed_2022_931422 crossref_primary_10_1016_j_blre_2022_100999 crossref_primary_10_1016_j_clon_2012_11_004 crossref_primary_10_1080_14712598_2020_1790522 crossref_primary_10_1634_theoncologist_2015_0377 crossref_primary_10_3390_cells11152308 crossref_primary_10_1007_s00520_014_2437_3 crossref_primary_10_1016_j_rcot_2020_07_015 crossref_primary_10_3389_fonc_2021_627282 crossref_primary_10_1007_s11639_015_0103_2 crossref_primary_10_1016_j_urology_2011_01_006 crossref_primary_10_1016_S0020_1383_17_30658_7 crossref_primary_10_1038_bonekey_2012_135 crossref_primary_10_1016_S1040_8428_11_70005_1 crossref_primary_10_1016_j_eururo_2014_10_001 crossref_primary_10_1002_jbmr_3606 crossref_primary_10_2217_fon_12_3 crossref_primary_10_3111_13696998_2011_632044 crossref_primary_10_4137_CMT_S2166 crossref_primary_10_1586_14737140_2014_947691 crossref_primary_10_2147_JPR_S386879 crossref_primary_10_1016_j_ejrad_2015_07_024 crossref_primary_10_3171_2014_4_SPINE13695 crossref_primary_10_1007_s40273_013_0121_y crossref_primary_10_1186_1471_2288_14_1 crossref_primary_10_1002_cam4_1668 crossref_primary_10_1016_j_rcot_2020_07_021 crossref_primary_10_1016_j_rcot_2020_07_022 crossref_primary_10_1097_MD_0000000000002014 crossref_primary_10_1016_j_wneu_2018_02_184 crossref_primary_10_1038_s41598_019_50636_9 crossref_primary_10_3389_fendo_2018_00436 crossref_primary_10_3390_ijms20236081 crossref_primary_10_1080_03007995_2016_1226166 crossref_primary_10_1080_14656566_2018_1504922 crossref_primary_10_1016_S1286_935X_21_45247_0 crossref_primary_10_1007_s12288_021_01470_5 crossref_primary_10_1007_s10585_019_09987_w crossref_primary_10_1038_leu_2008_336 crossref_primary_10_1016_j_otsr_2020_02_025 crossref_primary_10_1016_j_mednuc_2013_12_004 crossref_primary_10_1007_s10549_011_1475_5 crossref_primary_10_1016_j_jbo_2014_01_001 crossref_primary_10_3928_01477447_20200619_08 crossref_primary_10_1007_s12094_021_02695_6 crossref_primary_10_1016_j_drugalcdep_2019_01_025 crossref_primary_10_1007_s00520_013_2103_1 crossref_primary_10_1111_os_13236 crossref_primary_10_1155_2013_289458 crossref_primary_10_1186_s12885_020_07080_0 crossref_primary_10_1016_j_bone_2023_116957 crossref_primary_10_1002_jcp_26856 crossref_primary_10_1007_s00432_013_1427_z crossref_primary_10_1016_S1040_8428_11_70004_X crossref_primary_10_55095_achot2022_043 crossref_primary_10_1007_s00590_013_1293_z crossref_primary_10_1302_0301_620X_100B8_BJJ_2018_0300_R1 crossref_primary_10_1517_14656560902832684 crossref_primary_10_1007_s00774_022_01347_1 crossref_primary_10_1002_jbmr_3859 crossref_primary_10_1007_s12094_011_0634_9 crossref_primary_10_1016_j_spinee_2020_02_010 crossref_primary_10_1002_jso_27601 crossref_primary_10_1016_j_urology_2012_10_037 crossref_primary_10_1053_j_seminhematol_2010_11_001 crossref_primary_10_1166_jmihi_2021_3818 crossref_primary_10_1188_09_CJON_701_710 crossref_primary_10_7314_APJCP_2013_14_5_3357 crossref_primary_10_1136_bmj_2022_071565 crossref_primary_10_1016_j_medcli_2009_10_013 crossref_primary_10_1080_07357907_2020_1735407 crossref_primary_10_1007_s00330_014_3357_9 crossref_primary_10_1016_j_bone_2020_115299 crossref_primary_10_1159_000338650 crossref_primary_10_1007_s12307_011_0090_7 crossref_primary_10_1016_j_jbo_2012_06_001 crossref_primary_10_1007_s00262_019_02353_5 crossref_primary_10_1038_leu_2010_62 crossref_primary_10_1016_j_jos_2023_07_001 crossref_primary_10_1016_j_revmed_2010_11_007 crossref_primary_10_1002_jso_24222 crossref_primary_10_1093_neuonc_noad225 crossref_primary_10_1007_s00520_015_2887_2 crossref_primary_10_3390_cancers14040893 crossref_primary_10_7717_peerj_7822 crossref_primary_10_1016_j_ejmp_2023_103177 crossref_primary_10_3892_ol_2013_1372 crossref_primary_10_1016_j_ejca_2016_11_015 crossref_primary_10_1016_j_bone_2016_07_007 crossref_primary_10_1186_1748_717X_8_200 crossref_primary_10_4103_jcrt_JCRT_824_17 crossref_primary_10_1158_1078_0432_CCR_10_1804 crossref_primary_10_1016_j_actbio_2019_07_018 crossref_primary_10_3389_fbioe_2022_866970 crossref_primary_10_1016_j_jgo_2014_04_001 crossref_primary_10_1097_CAD_0000000000000339 crossref_primary_10_1016_j_semcdb_2015_11_007 crossref_primary_10_1097_01_REO_0000000000000241 crossref_primary_10_1002_hon_2486 crossref_primary_10_1016_j_jbo_2016_02_006 crossref_primary_10_1007_s12609_010_0025_1 crossref_primary_10_1002_cam4_2608 crossref_primary_10_23736_S1824_4785_23_03537_9 crossref_primary_10_1002_jso_22061 crossref_primary_10_1016_j_rccot_2017_03_009 crossref_primary_10_1155_2020_4173578 crossref_primary_10_1055_s_0042_1745740 crossref_primary_10_1016_j_otsr_2020_03_034 crossref_primary_10_1111_ecc_12490 crossref_primary_10_1158_1078_0432_CCR_10_0600 crossref_primary_10_1007_s00264_009_0921_z crossref_primary_10_1016_j_mporth_2012_02_002 crossref_primary_10_1634_theoncologist_2015_0527 crossref_primary_10_3892_ol_2014_1982 crossref_primary_10_1016_j_spinee_2023_01_008 crossref_primary_10_1038_leu_2011_43 crossref_primary_10_1007_s00113_016_0282_1 crossref_primary_10_1002_jcb_22403 crossref_primary_10_1185_03007995_2012_689254 crossref_primary_10_1007_s00256_019_03288_9 crossref_primary_10_3109_10428194_2012_746683 crossref_primary_10_1007_s00259_011_1920_z crossref_primary_10_1007_s00520_018_4489_2 crossref_primary_10_1038_s41375_018_0161_6 crossref_primary_10_1177_030089161309900101 crossref_primary_10_3390_cells11081309 crossref_primary_10_3892_mco_2024_2749 crossref_primary_10_1016_j_cllc_2013_05_002 crossref_primary_10_1038_leu_2015_342 crossref_primary_10_2214_AJR_18_20700 crossref_primary_10_1038_s41391_022_00569_8 crossref_primary_10_1002_tre_853 crossref_primary_10_3109_00365590903295193 crossref_primary_10_3109_07357907_2010_483508 crossref_primary_10_4236_jct_2014_54045 crossref_primary_10_1016_j_achaem_2014_04_010 crossref_primary_10_1038_s41419_018_1203_8 crossref_primary_10_1016_j_rcl_2011_07_004 crossref_primary_10_1016_j_medcli_2009_07_040 crossref_primary_10_3348_kjr_2018_0545 crossref_primary_10_23736_S0394_3410_19_03960_2 crossref_primary_10_1016_j_bone_2010_06_016 crossref_primary_10_1016_j_jgo_2014_03_002 crossref_primary_10_1586_ecp_12_21 crossref_primary_10_1007_s00520_016_3431_8 crossref_primary_10_1586_era_11_204 crossref_primary_10_1186_2193_1801_3_328 crossref_primary_10_1002_cncr_31237 crossref_primary_10_1016_j_micron_2017_01_009 crossref_primary_10_3111_13696998_2011_649324 crossref_primary_10_1007_s12094_013_1033_1 crossref_primary_10_1111_bph_14889 crossref_primary_10_1016_j_bone_2020_115598 crossref_primary_10_1016_j_ejca_2012_07_016 crossref_primary_10_1016_j_breast_2011_08_138 crossref_primary_10_3928_01477447_20100625_20 crossref_primary_10_1007_s00270_023_03425_x crossref_primary_10_1016_S1470_2045_11_70008_0 crossref_primary_10_1007_s00590_008_0406_6 crossref_primary_10_1016_j_breast_2014_05_023 crossref_primary_10_3390_ijms21186913 crossref_primary_10_1016_j_jvir_2021_03_523 crossref_primary_10_1002_cdt3_35 crossref_primary_10_1302_2058_5241_1_000008 crossref_primary_10_1016_j_oto_2021_100899 crossref_primary_10_1097_CAD_0000000000000169 crossref_primary_10_1016_j_ejca_2016_05_014 crossref_primary_10_1007_s00132_012_1909_8 crossref_primary_10_1016_j_suronc_2021_101618 crossref_primary_10_1200_EDBK_205583 crossref_primary_10_1016_j_critrevonc_2009_03_001 crossref_primary_10_1517_14712590902845610 crossref_primary_10_1007_s00264_010_1127_0 crossref_primary_10_1038_s41467_020_20715_x crossref_primary_10_1186_s13256_024_04604_1 crossref_primary_10_1016_j_ctrv_2012_07_002 |
Cites_doi | 10.2165/00003495-200161090-00003 10.1093/jnci/94.19.1458 10.1002/14651858.CD003474.pub2 10.1200/JCO.1998.16.2.593 10.2165/00002512-200118120-00002 10.1016/j.berh.2005.06.003 10.1093/annonc/mdi122 10.1016/S0022-5347(05)64561-2 10.1200/JCO.2003.08.017 10.1002/cncr.11701 10.1046/j.1532-5415.2003.51110.x 10.1002/cncr.20308 10.1002/(SICI)1097-0142(19971015)80:8 <1588::AID-CNCR9>3.0.CO;2-G 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z 10.1093/jnci/djh141 10.1093/annonc/mdi162 10.1200/JCO.1999.17.3.846 10.1359/jbmr.2003.18.7.1254 10.1159/000084518 10.1200/JCO.2003.04.105 10.1016/S0960-9776(05)80140-7 10.1002/jbmr.5650090521 10.3816/CLC.2004.n.030 10.1200/JCO.2002.06.037 10.1007/s00198-003-1412-5 10.1302/0301-620X.87B5.16021 10.1200/JCO.2005.05.116 10.1016/j.eururo.2004.08.016 10.1586/14737140.5.2.221 10.1200/JCO.1998.16.6.2038 |
ContentType | Journal Article |
Copyright | Copyright © 2007 American Cancer Society 2007 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2007 American Cancer Society – notice: 2007 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1002/cncr.22991 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0142 |
EndPage | 1867 |
ExternalDocumentID | 10_1002_cncr_22991 17763372 19139264 CNCR22991 |
Genre | article Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Novartis Pharmaceuticals Corp., East Hanover, New Jersey |
GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AARRQ AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AGNAY AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M J5H JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NEJ NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ 08R 3O- AAJUZ AAUGY AAVGM ABCVL ABHUG ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS AI. AKALU EMOBN HF~ H~9 IQODW OHT RSU VH1 WHG XFK Y6R YQJ ZA5 ZXP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c3931-a2fa896c867dae7fc15a2f7104c550dd4e6d842f4086c623e914c24c7806d2323 |
IEDL.DBID | DR2 |
ISSN | 0008-543X |
IngestDate | Fri Aug 16 01:30:43 EDT 2024 Fri Aug 23 00:55:36 EDT 2024 Thu May 23 23:11:41 EDT 2024 Sun Oct 22 16:08:36 EDT 2023 Sat Aug 24 01:01:22 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Antineoplastic agent Prostate carcinoma Pathologic fracture Prostate disease lung carcinoma Lung cancer Diseases of the osteoarticular system Diphosphonic acid derivatives skeletal metastases Metastasis Myeloma Bronchopulmonary carcinoma Bisphosphonates Osteoarticular system Breast carcinoma Cancerology Immunoglobulinopathy Lymphoproliferative syndrome Zoledronic acid bisphosphonate Bronchus disease Skeleton Male genital diseases Human Immunopathology Lung disease multiple myeloma Urinary system disease Respiratory disease Malignant hemopathy Breast cancer Malignant tumor Survival Mammary gland diseases Bone Prostate cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3931-a2fa896c867dae7fc15a2f7104c550dd4e6d842f4086c623e914c24c7806d2323 |
Notes | Fax: (514) 412‐7824 Fred Saad and Richard Cook are on the advisory board of and receive honoraria from Novartis. Richard Cook and Robert Coleman serve as consultants to Novartis, and Robert Coleman also receives honoraria from Novartis. Allan Lipton is a consultant to and receives honoraria from Amgen and Novartis. Yen‐Miao Chen is an employee of Novartis. Matthew R. Smith serves as a consultant to Novartis Oncology, Amgen, and GTX. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.22991 |
PMID | 17763372 |
PQID | 68356687 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_68356687 crossref_primary_10_1002_cncr_22991 pubmed_primary_17763372 pascalfrancis_primary_19139264 wiley_primary_10_1002_cncr_22991_CNCR22991 |
PublicationCentury | 2000 |
PublicationDate | 15 October 2007 |
PublicationDateYYYYMMDD | 2007-10-15 |
PublicationDate_xml | – month: 10 year: 2007 text: 15 October 2007 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: New York, NY – name: United States |
PublicationTitle | Cancer |
PublicationTitleAlternate | Cancer |
PublicationYear | 2007 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
References | 1997; 80 2004; 100 2002; 94 2000; 88 2004; 46 2003; 14 2004; 6 2005; 87 2005 2004 2003; 18 2003; 51 2003; 52 2005; 23 2003; 98 2005; 68 1998; 16 1994; 9 2004; 96 2001; 61 2005; 19 2001; 7 2002; 20 1999; 17 2002; 168 2005; 5 2001; 18 2005; 16 2005; 18 2003; 21 2005; 14 Rosen LS (e_1_2_5_20_2) 2001; 7 e_1_2_5_24_2 e_1_2_5_25_2 e_1_2_5_22_2 e_1_2_5_23_2 e_1_2_5_21_2 Green JR (e_1_2_5_35_2) 1994; 9 e_1_2_5_28_2 e_1_2_5_29_2 Coleman RE (e_1_2_5_4_2) 2004 e_1_2_5_14_2 e_1_2_5_13_2 Rodriguez Garcia M (e_1_2_5_26_2) 2005; 18 e_1_2_5_9_2 e_1_2_5_16_2 e_1_2_5_8_2 e_1_2_5_15_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_33_2 e_1_2_5_6_2 e_1_2_5_34_2 e_1_2_5_5_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_11_2 e_1_2_5_32_2 e_1_2_5_3_2 e_1_2_5_2_2 e_1_2_5_18_2 e_1_2_5_17_2 e_1_2_5_19_2 Truumees E (e_1_2_5_27_2) 2003; 52 e_1_2_5_30_2 |
References_xml | – volume: 94 start-page: 1458 year: 2002 end-page: 1468 article-title: A randomized, placebo‐controlled trial of zoledronic acid in patients with hormone‐refractory metastatic prostate carcinoma publication-title: J Natl Cancer Inst. – volume: 18 start-page: 899 year: 2001 end-page: 911 article-title: Strategies for management of prostate cancer‐related bone pain publication-title: Drugs Aging. – start-page: 1091 year: 2004 end-page: 1128 – volume: 96 start-page: 879 year: 2004 end-page: 882 article-title: Long‐term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone‐refractory prostate cancer publication-title: J Natl Cancer Inst. – volume: 20 start-page: 3719 year: 2002 end-page: 3736 article-title: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma publication-title: J Clin Oncol. – volume: 98 start-page: 1735 year: 2003 end-page: 1744 article-title: Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double‐blind, multicenter, comparative trial publication-title: Cancer. – volume: 21 start-page: 4042 year: 2003 end-page: 4057 article-title: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer publication-title: J Clin Oncol. – volume: 88 start-page: 1082 year: 2000 end-page: 1090 article-title: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow‐up of 2 randomized, placebo‐controlled trials publication-title: Cancer. – volume: 61 start-page: 1253 year: 2001 end-page: 1274 article-title: The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma publication-title: Drugs. – volume: 46 start-page: 731 year: 2004 end-page: 739 article-title: Skeletal morbidity in men with prostate cancer: quality‐of‐life considerations throughout the continuum of care publication-title: Eur Urol. – volume: 17 start-page: 846 year: 1999 end-page: 854 article-title: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo‐controlled trial publication-title: J Clin Oncol. – volume: 80 start-page: 1588 year: 1997 end-page: 1594 article-title: Skeletal complications of malignancy publication-title: Cancer. – start-page: CD003474 year: 2005 article-title: Bisphosphonates for breast cancer publication-title: Cochrane Database Syst Rev. – volume: 16 start-page: 593 year: 1998 end-page: 602 article-title: Long‐term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events publication-title: J Clin Oncol. – volume: 51 start-page: 364 year: 2003 end-page: 370 article-title: Estimating hip fracture morbidity, mortality and costs publication-title: J Am Geriatr Soc. – volume: 168 start-page: 1005 year: 2002 end-page: 1007 article-title: Skeletal fractures negatively correlate with overall survival in men with prostate cancer publication-title: J Urol. – volume: 7 start-page: 377 year: 2001 end-page: 387 article-title: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial publication-title: Cancer J. – volume: 18 start-page: 458 year: 2005 end-page: 463 article-title: Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence publication-title: J Nephrol. – volume: 87 start-page: 608 year: 2005 end-page: 617 article-title: Controversies in the surgical management of skeletal metastases publication-title: J Bone Joint Surg Br. – volume: 18 start-page: 1254 year: 2003 end-page: 1260 article-title: Association between vertebral fracture and increased mortality in osteoporotic patients publication-title: J Bone Miner Res. – volume: 16 start-page: 2038 year: 1998 end-page: 2044 article-title: Long‐term prevention of skeletal complications of metastatic breast cancer with pamidronate publication-title: J Clin Oncol. – volume: 16 start-page: 579 year: 2005 end-page: 584 article-title: The significance of skeletal‐related events for the health‐related quality of life of patients with metastatic prostate cancer publication-title: Ann Oncol. – volume: 19 start-page: 879 year: 2005 end-page: 895 article-title: How many people develop fractures with what outcome? publication-title: Best Pract Res Clin Rheumatol. – volume: 14 start-page: 589 year: 2003 end-page: 594 article-title: Incident vertebral fractures and mortality in older women: a prospective study publication-title: Osteoporos Int. – volume: 16 start-page: 687 year: 2005 end-page: 695 article-title: Bisphosphonates in breast cancer publication-title: Ann Oncol. – volume: 14 start-page: S44 year: 2005 article-title: Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases [abstract] publication-title: Breast. – volume: 5 start-page: 221 year: 2005 end-page: 230 article-title: Clodronate in the prevention and treatment of skeletal metastasis publication-title: Expert Rev Anticancer Ther. – volume: 9 start-page: 747 year: 1994 end-page: 751 article-title: Preclinical pharmacology of GCP 42′466, a new, potent, heterocyclic bisphosphonate compound publication-title: J Bone Miner Res. – volume: 100 start-page: 2613 year: 2004 end-page: 2621 article-title: Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double‐blind, placebo‐controlled trial publication-title: Cancer. – volume: 68 start-page: 18 year: 2005 end-page: 22 article-title: The role of bisphosphonates in the management of advanced cancer with a focus on non‐small‐cell lung cancer. Part 2. Clinical studies and economic analyses publication-title: Oncology. – volume: 23 start-page: 3314 year: 2005 end-page: 3321 article-title: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo‐controlled trial publication-title: J Clin Oncol. – volume: 52 start-page: 551 year: 2003 end-page: 558 article-title: Medical consequences of osteoporotic vertebral compression fractures publication-title: Instr Course Lect. – volume: 6 start-page: 170 year: 2004 end-page: 174 article-title: Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications publication-title: Clin Lung Cancer. – volume: 21 start-page: 3150 year: 2003 end-page: 3157 article-title: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double‐blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group publication-title: J Clin Oncol. – ident: e_1_2_5_3_2 doi: 10.2165/00003495-200161090-00003 – ident: e_1_2_5_8_2 doi: 10.1093/jnci/94.19.1458 – ident: e_1_2_5_10_2 doi: 10.1002/14651858.CD003474.pub2 – ident: e_1_2_5_22_2 doi: 10.1200/JCO.1998.16.2.593 – start-page: 1091 volume-title: Clinical Oncology year: 2004 ident: e_1_2_5_4_2 contributor: fullname: Coleman RE – ident: e_1_2_5_5_2 doi: 10.2165/00002512-200118120-00002 – ident: e_1_2_5_25_2 doi: 10.1016/j.berh.2005.06.003 – ident: e_1_2_5_6_2 doi: 10.1093/annonc/mdi122 – ident: e_1_2_5_19_2 doi: 10.1016/S0022-5347(05)64561-2 – ident: e_1_2_5_11_2 doi: 10.1200/JCO.2003.08.017 – ident: e_1_2_5_16_2 doi: 10.1002/cncr.11701 – ident: e_1_2_5_24_2 doi: 10.1046/j.1532-5415.2003.51110.x – ident: e_1_2_5_9_2 doi: 10.1002/cncr.20308 – ident: e_1_2_5_2_2 doi: 10.1002/(SICI)1097-0142(19971015)80:8 <1588::AID-CNCR9>3.0.CO;2-G – ident: e_1_2_5_14_2 doi: 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z – ident: e_1_2_5_18_2 doi: 10.1093/jnci/djh141 – ident: e_1_2_5_33_2 doi: 10.1093/annonc/mdi162 – ident: e_1_2_5_15_2 doi: 10.1200/JCO.1999.17.3.846 – ident: e_1_2_5_29_2 doi: 10.1359/jbmr.2003.18.7.1254 – ident: e_1_2_5_32_2 doi: 10.1159/000084518 – ident: e_1_2_5_21_2 doi: 10.1200/JCO.2003.04.105 – volume: 7 start-page: 377 year: 2001 ident: e_1_2_5_20_2 article-title: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double‐blind, comparative trial publication-title: Cancer J. contributor: fullname: Rosen LS – volume: 18 start-page: 458 year: 2005 ident: e_1_2_5_26_2 article-title: Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence publication-title: J Nephrol. contributor: fullname: Rodriguez Garcia M – ident: e_1_2_5_17_2 doi: 10.1016/S0960-9776(05)80140-7 – volume: 9 start-page: 747 year: 1994 ident: e_1_2_5_35_2 article-title: Preclinical pharmacology of GCP 42′466, a new, potent, heterocyclic bisphosphonate compound publication-title: J Bone Miner Res. doi: 10.1002/jbmr.5650090521 contributor: fullname: Green JR – volume: 52 start-page: 551 year: 2003 ident: e_1_2_5_27_2 article-title: Medical consequences of osteoporotic vertebral compression fractures publication-title: Instr Course Lect. contributor: fullname: Truumees E – ident: e_1_2_5_28_2 doi: 10.3816/CLC.2004.n.030 – ident: e_1_2_5_12_2 doi: 10.1200/JCO.2002.06.037 – ident: e_1_2_5_30_2 doi: 10.1007/s00198-003-1412-5 – ident: e_1_2_5_31_2 doi: 10.1302/0301-620X.87B5.16021 – ident: e_1_2_5_7_2 doi: 10.1200/JCO.2005.05.116 – ident: e_1_2_5_23_2 doi: 10.1016/j.eururo.2004.08.016 – ident: e_1_2_5_34_2 doi: 10.1586/14737140.5.2.221 – ident: e_1_2_5_13_2 doi: 10.1200/JCO.1998.16.6.2038 |
SSID | ssj0007253 |
Score | 2.4983199 |
Snippet | BACKGROUND.
Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival... Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients... Abstract BACKGROUND. Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on... BACKGROUNDData from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in... |
SourceID | proquest crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1860 |
SubjectTerms | Adult Aged Aged, 80 and over Biological and medical sciences bisphosphonate breast carcinoma Double-Blind Method Female Fractures, Bone - mortality Gynecology. Andrology. Obstetrics Humans lung carcinoma Male Mammary gland diseases Medical sciences Middle Aged multiple myeloma Neoplasms - mortality prostate carcinoma Retrospective Studies Risk Factors skeletal metastases Survival Rate Tumors zoledronic acid |
Title | Pathologic fractures correlate with reduced survival in patients with malignant bone disease |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.22991 https://www.ncbi.nlm.nih.gov/pubmed/17763372 https://search.proquest.com/docview/68356687 |
Volume | 110 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1LS8QwEMcH8SCC-H7UZ0BPQtfdNE1T8CKLIoIiorAHpaRJKqJW2W4vfnpn2q5lRQS9lZKQNpNMfskk_wAcdC0yB1c93ygnfAqt-SrNjB9obaUhhNcU0b28kud34mIQDqbgeHwWptaH-Fpwo55R-Wvq4DotjlrRUJObYYejN6W5DynpERHdtNpREW8kKLvKD0Uw-NIm5Udt1onRaO5dF1gxWX2jxU_IOUmw1RB0tgAP44-vd548d8pR2jEf33Qd__t3izDfsCk7qRvTEky5fBlmLpvo-wrcX-tR4yxZRqerSpyrM0P3e7wgsjJa02VD0oJ1lhUlOiFsxuwpZ414a1GneEX0f6T9Nyx9yx1rQkSrcHd2ets_95vbGXwTxEHP1zzTKpZGychqF2WmF-IrBBZhcNZjrXDSKsEzgZMmg5Dl4p4wXJhIdaVFjgvWYDrHYjaAcRsbLWMTOkmDaowI4WxoFbcpF5kMPdgfWyl5r0U4klpumSdUUUlVUR7sThiwTUrSpwh-HuyNLZpgJ6LIiM7dW1kkEjlUShV5sF4bus0boQMOIu7BYWWuX8pP-lf9m-pp8y-Jt2C2Wi-mXTLhNkyPhqXbQdAZpbtVg_4E9Av5jQ |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS9xAEB9EwQpi1foR2-qCfSrkvNtsNpvHclTO1jtEFO6hEDa7GxE1yuXy4l_vzCYarpRC-xbCLiE7O7O_-djfAHzpW8QcXA1Co5wIKbUWqrwwYaS1lYYgvKaM7ngiR9fixzSetrU5dBem4Yd4C7iRZnh7TQpOAemTjjXUlGbW42hO0flZQX2PvUd12bFHJbwloeyrMBbR9I2dlJ90cxfOo_UnXeHSFE1Piz-BzkUM6w-h0_dNp9XKcxdS7cldr57nPfP8G7Pjf__fJmy08JR9a_bTFiy5chtWx20C_gP8utDz1l6ygi5Y1eiuM0MtPu4RtTIK67IZ0cE6y6oa7RDuZHZbspa_tWpGPCD6v6ESHJY_lo61WaIduD79fjUchW2DhtBEaTQINS-0SqVRMrHaJYUZxPgKMYsw6PhYK5y0SvBCoN9kEGe5dCAMFyZRfWkRykW7sFziZ_aBcZsaLVMTO0nnaooowtnYKm5zLgoZB3D8KqbsqeHhyBrGZZ7RQmV-oQI4XJBgN5TYTxH7BXD0KtIM9YiSI7p0j3WVSYSiUqokgL1G0t3cBG1wlPAAvnp5_eX72XAyvPRPB_8y-Ajeja7G59n52eTnR1jz4WMqmok_wfJ8VrvPiHvm-aHf3S-U5f2v |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFD6IwhDE-6VeA_okdG5pmqbgi2wOr0NEYQ9KSZNURK1jW1_89Z60nWUigr6VkpA255Lv5CTfAThoaMQcVDRdJQxzbWrNFXGiXE9KzZWF8NJmdK-7_OyeXfT83hQcj-_CFPwQXxtu1jJyf20NvK-To4o0VKVqUKfoTTH2mWHco1an27cVeVRASw7KhnB95vW-yEnpUdV3Yjma68shzkxSlLT4CXNOQth8DeoswOP464ujJy_1bBTX1cc3Ysf__t4izJfglJwU2rQEUyZdhtp1mX5fgYcbOSq9JUns9aoMg3WibIGPV8SsxG7qkoElgzWaDDP0QqjH5DklJXvrsGjxhtj_yR7AIfF7akiZI1qF-87pXevMLcszuMoLvaYraSJFyJXggZYmSFTTx1eIWJjCsEdrZrgWjCYMoyaFKMuETaYoU4FocI1AzluD6RSH2QBCdagkD5VvuF1VQ8QQRvtaUB1TlnDfgf2xlKJ-wcIRFXzLNLITFeUT5cDuhACrppb7FJGfA3tjiUZoRTY1IlPzng0jjkCUcxE4sF4IuuoboAf2AurAYS6uX8aPWt3Wbf60-ZfGe1C7aXeiq_Pu5RbM5nvH9sSMvw3To0FmdhD0jOLdXLc_Aadg_F4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pathologic+fractures+correlate+with+reduced+survival+in+patients+with+malignant+bone+disease&rft.jtitle=Cancer&rft.au=Saad%2C+Fred&rft.au=Lipton%2C+Allan&rft.au=Cook%2C+Richard&rft.au=Chen%2C+Yin%E2%80%90Miao&rft.date=2007-10-15&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=110&rft.issue=8&rft.spage=1860&rft.epage=1867&rft_id=info:doi/10.1002%2Fcncr.22991&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_cncr_22991 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |